Fospropofol, a phosphorylated prodrug version of the popular induction agent propofol, is hydrolyzed in vivo to release active propofol, formaldehyde, and phosphate. Pharmacodynamic studies show fospropofol provides clinically useful sedation and EEG/bispectral index suppression while causing significantly less respiratory depression than propofol. Pain at the injection site, a common complaint with propofol, was not reported with fospropofol; the major patient complaint was transitory perianal itching during the drug's administration. Although many clinicians believe fospropofol can safely be given by a registered nurse, the FDA mandated that fospropofol, like propofol, must be used only in the presence of a trained anesthesia provider. © 2009 Harris et al, publisher and licensee Dove Medical Press Ltd.
CITATION STYLE
Harris, E. A., Lubarsky, D. A., & Candiotti, K. A. (2009). Monitored anesthesia care (MAC) sedation: Clinical utility of fospropofol. Therapeutics and Clinical Risk Management. https://doi.org/10.2147/tcrm.s5583
Mendeley helps you to discover research relevant for your work.